Sebastian Graf, Bhaskar K Somani
PURPOSE OF REVIEW: Management of stone disease in pregnancy poses a challenge for all healthcare professionals involved in their care. During pregnancy, there is an increase in the incidence of urolithiasis. Major technological and procedural advances have been seen in the last decade for endoscopic management of urolithiasis. The purpose of this review is to provide a comprehensive workup of available literature on use of ureteroscopy for stone treatment during pregnancy. RECENT FINDINGS: We identified 268 articles on screening, of which 28 were included in the final review...
September 20, 2023: Current Opinion in Urology
Antoine Valeri, Truong An Nguyen
PURPOSE OF REVIEW: Tumor volume and heterogenicity are associated with diagnosis and prognosis of urological cancers, and assessed by conventional imaging. Quantitative imaging, Radiomics, using advanced mathematical analysis may contain information imperceptible to the human eye, and may identify imaging-based biomarkers, a new field of research for individualized medicine. This review summarizes the recent literature on radiomics in kidney and prostate cancers and the future perspectives...
September 19, 2023: Current Opinion in Urology
Oumar Gaye, Cheikh Bintou Fall, Mohamed Jalloh, Babacar Faye, Marc Jobin, Olivier Cussenot
PURPOSE OF REVIEW: Urine volatile organic compound (VOC) testing for early detection of urological cancers is a minimally invasive and promising method. The objective of this review was to present the results of recently published work on this subject. RECENT FINDINGS: Organic volatile compounds are produced through oxidative stress and peroxidation of cell membranes, and they are eliminated through feces, urine, and sweat. Studies looking for VOCs in urine for the diagnosis of urological cancers have mostly focused on bladder and prostate cancers...
September 6, 2023: Current Opinion in Urology
Igor Tsaur, Cristian Mirvald, Cristian Surcel
PURPOSE OF REVIEW: Over the last years, there have been striking changes in the management of metastatic hormone-sensitive prostate cancer (mHSPC) based on survival advantage of combining either a new hormonal agent (NHA) or docetaxel (D) with androgen deprivation therapy (ADT). Some of these studies primarily assessing doublet treatment included men who underwent concomitant or sequential treatment with D. Most recently, prospective randomized evidence emerged on this triplet strategy too...
September 4, 2023: Current Opinion in Urology
Xiaobo Wu, Chris Ho-Ming Wong, Giorgio Gandaglia, Peter Ka-Fung Chiu
PURPOSE OF REVIEW: Urinary incontinence is common postoperative complication following robot-assisted radical prostatectomy (RARP) in patients with prostate cancer (PCa). Despite the increasing adoption of RARP in the treatment of high-risk PCa (HRPC), concerns persist regarding the adequacy of reported continence outcomes in this subgroup. This review aims to illuminate the state of continence recovery in HRPC patients post-RARP. RECENT FINDINGS: Urinary continence (UC) recovery rates in HRPC was reported to be lower than the intermediate/low-risk counterparts from 6 to 24 months post-RARP...
August 31, 2023: Current Opinion in Urology
Géraldine Cancel-Tassin, Stella Koutros
PURPOSE OF REVIEW: Urologic cancers result from the appearance of genomic alterations in the target organ due to the combination of genetic and environmental factors. Knowledge of the genomic markers involved in their etiology and mechanisms for their development continue to progress. This reviewed provides an update on recent genomic studies that have informed epidemiologic and clinical research in urology. RECENT FINDINGS: Inherited variations are an established risk factor for urologic cancers with significant estimates of heritability for prostate, kidney, and bladder cancer...
August 30, 2023: Current Opinion in Urology
Sabrina De Cillis, Nadir Osman, Cyrille Guillot-Tantay, Francois Hervé, Mikolaj Przydacz, Manuela Tutolo, Gokhan Culha, Paolo Geretto, Fabiana Cancrini, Enrico Checcucci, Veronique Phé
PURPOSE OF REVIEW: The aim of this narrative review is to evaluate the current available literature on urinary outcomes following cryotherapy and high-intensity focused ultrasound (HIFU) for localized prostate cancer (PCa). RECENT FINDINGS: The available literature is heterogeneous in terms of intervention modalities and assessment of urinary outcome measures. Nevertheless, ultra-minimally invasive treatments seem to provide good urinary outcomes. Technological advancement and the adoption of more conservative ablation templates allow for a further reduction of toxicity and better preservation of urinary function...
August 23, 2023: Current Opinion in Urology
Stefan Plas, Andreas Pircher, Isabel Heidegger
PURPOSE OF REVIEW: Immune checkpoint inhibitors (ICIs) have shown promising antitumor activity in various malignant diseases. This narrative review provides an update on ongoing clinical studies investigating the only FDA-approved ICI programmed death receptor 1 (PD-1) inhibitor pembrolizumab in mono- and combination therapy in patients with metastatic castration-resistant prostate cancer (mCRPC). RECENT FINDINGS: Although most clinical trials investigating pembrolizumab as mono- or combinational therapy did not meet their primary endpoints, there exist subgroups of patients that demonstrate impressive responses rates justifying further investigation of ICI in prostate cancer...
August 22, 2023: Current Opinion in Urology
Fabio Zattoni, Pawel Rajwa, Giorgio Gandaglia
PURPOSE OF REVIEW: To evaluate the evidence supporting treatment intensification in mHSPC, with a focus on possible indications for treatment in each clinical setting. RECENT FINDINGS: There is a growing armamentarium of treatment options for patients with metastatic hormone-sensitive prostate cancer (mHSPC). These include combinations of treatments such as androgen deprivation therapy (ADT), docetaxel, and new antiandrogenic therapies. Treatment intensification with chemotherapy or newer hormonal agents may improve patient's oncologic outcomes, but it can also come with additional toxicities and costs...
August 22, 2023: Current Opinion in Urology
Andrea Gallioli, Giuseppe Basile, Angelo Territo, Alberto Breda
PURPOSE OF REVIEW: Nephron-sparing surgery (NSS) is the preferred treatment in patients with low-risk upper tract urothelial carcinoma (UTUC). Improving both instruments and topical chemotherapy regimens efficacy is crucial to achieve better outcomes. The purpose of this review is to summarize the most recent evidence on technological advances for the conservative management of UTUC with implications on diagnosis and treatment. RECENT FINDINGS: Novel diagnostic tools, lasers, and topical chemotherapy systems delivery have been implemented to optimize NSS outcomes for UTUC...
August 21, 2023: Current Opinion in Urology
Olivier Cussenot, Gaelle Fromont, Géraldine Cancel-Tassin, Freddie C Hamdy, Richard M Martin
PURPOSE OF REVIEW: Many studies on epidemiology of prostate cancer (PCa) are based on a diagnosis of PCa using PSA (prostate-specific antigen) level. However, biases can distort the interpretation of the results, which in turn limits policy and decision making on public health prevention strategies or clinical guidelines. The main confusion is to interpret the posterior probability of the outcome following the exposure as a change in the prevalence of the disease outcome, whereas this change reflects only the predictive values of the PSA test induced by the exposure of interest...
August 9, 2023: Current Opinion in Urology
Francesco Barletta, Francesco Ceci, Roderick C N van den Bergh, Pawel Rajwa, Francesco Montorsi, Alberto Briganti, Giorgio Gandaglia
PURPOSE OF REVIEW: There has been a growing interest in the use of novel molecular imaging modalities for the management of prostate cancer (PCa), spanning from diagnostic to therapeutic settings. The aim of this review is to provide a comprehensive overview of recently published studies investigating the use of novel nuclear medicine tracers across different stages of PCa management. RECENT FINDINGS: Emerging evidence supports the use of molecular imaging for preoperative staging of PCa, where prostate-specific membrane antigen (PSMA) PET has shown superior accuracy compared to conventional imaging for the detection of nodal and distant metastases, which needs to be translated to new risk stratification...
August 3, 2023: Current Opinion in Urology
Jamaal C Jackson, Antonio Franco, Dian Wang, Riccardo Autorino, Srinivas Vourganti
PURPOSE OF REVIEW: To provide a critical overview of the latest evidence on the role of metastasis-direct treatment (MDT) in the management of metastatic renal cell carcinoma (mRCC). RECENT FINDINGS: This is a nonsystematic review of the English language literature published since January 2021. A PubMed/MEDLINE search using various search terms was conducted, including only original studies. After title and abstract screening, selected articles were grouped into two main areas which mirror the main treatment options in this setting: surgical metastasectomy (MS) and stereotactic radiotherapy (SRT)...
July 6, 2023: Current Opinion in Urology
Mario de Angelis, Giuseppe Basile, Carlo Maria Scornajenghi, Vincenzo Asero, Francesco Del Giudice, Marco Moschini
PURPOSE OF REVIEW: Radical cystectomy is the standard of care for patients with localized muscle-invasive bladder cancer (MIBC). In this context, bladder-sparing strategies (BSS) have been investigated as viable alternatives for patients who are unfit for radical cystectomy or aim to preserve their bladder without compromising oncological outcomes. This review aims to provide the most up-to-date evidence on BSSs as an alternative treatment for patients with MIBC. RECENT FINDINGS: Different studies have highlighted the long-term efficacy of trimodal therapy or chemoradiation protocols...
July 3, 2023: Current Opinion in Urology
Carlo Maria Scornajenghi, Vincenzo Asero, Eugenio Bologna, Giuseppe Basile, Mario De Angelis, Marco Moschini, Francesco Del Giudice
PURPOSE OF REVIEW: Penile cancer (PeCa) is an orphan disease due to its rare incidence in high-income countries. Traditional surgical options for clinical T1-2 disease, including partial and total penectomy, can dramatically affect patient's quality of life and mental health status. In selected patients, organ-sparing surgery (OSS) has the potential to remove the primary tumor with comparable oncologic outcomes while maintaining penile length, sexual and urinary function. In this review, we aim to discuss the indications, advantages, and outcomes of various OSSs currently available for men diagnosed with PeCa seeking an organ-preserving option...
June 29, 2023: Current Opinion in Urology
Marcello Della Corte, Francesco Porpiglia, Enrico Checcucci
No abstract text is available yet for this article.
September 1, 2023: Current Opinion in Urology
(no author information available yet)
No abstract text is available yet for this article.
September 1, 2023: Current Opinion in Urology
Celestia S Higano, Heather H Cheng
PURPOSE OF REVIEW: The landscape for first-line therapy (1L) of metastatic castration-resistant prostate cancer (mCRPC) is rapidly shifting. In the past 2 years, three phase 3 trials have examined the addition of a poly-ADP ribose polymerase inhibitor (PARPi) to an androgen receptor-signaling inhibitor (ARSI) in 1L. The FDA and the EMA recently considered whether one of these combinations should be approved for "all comers." Here, we review the trial designs, assays for homologous recombination repair mutations (HRRm) and BRCA mutations ( BRCA m), and predictive capacity of mutational status on treatment efficacy to understand the basis for the FDA decision...
September 1, 2023: Current Opinion in Urology
Angela Pecoraro, Riccardo Campi, Michele Marchioni
PURPOSE OF REVIEW: Small renal masses suspected to be malignant have little potential for metastasis and disease-related mortality. Surgery remains the standard care but represents overtreatment in many cases. Percutaneous ablative technique, especially thermal ablation has emerged as a valid alternative. RECENT FINDINGS: The increased availability of cross-sectional imaging has led to a large number of incidentally detected small renal masses (SRMs), many of which are of low grade and exhibit indolent behaviour...
September 1, 2023: Current Opinion in Urology
Susan F Slovin
PURPOSE OF REVIEW: Immunotherapy, a treatment modality currently synonymous with immune checkpoint blockade remains a challenge for prostate cancer. Despite multiple phase 3 trials using checkpoint inhibitors in combinatorial approaches, there have been no benefits to date in overall survival or radiographic progression free survival. However, newer strategies prevail that are directed to a variety of unique cell surface antigens. These strategies include unique vaccines, chimeric antigen receptor (CAR) T, bispecific T cell engager platforms, and antibody-drug conjugates...
September 1, 2023: Current Opinion in Urology
Fetch more papers »
Fetching more papers... Fetching...
Remove bar
Read by QxMD icon Read

Save your favorite articles in one place with a free QxMD account.


Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"

We want to hear from doctors like you!

Take a second to answer a survey question.